Anti-EGFR antibody monotherapy for colorectal cancer with severe hyperbilirubinemia: A case report  

作　　者：Toshiaki Tsurui Yuya Hirasawa Yutaro Kubota Kiyoshi Yoshimura Takuya Tsunoda 

机构地区：[1]Department of Medical Oncology,Showa University,Tokyo 1428555,Japan [2]Department of Clinical Immuno Oncology,Clinical Research Institute of Clinical Pharmacology and Therapeutics,Showa University,Tokyo 1578577,Japan

出　　处：《World Journal of Gastrointestinal Oncology》2024年第2期557-562,共6页世界胃肠肿瘤学杂志（英文版）（电子版）

摘　　要：BACKGROUND Hyperbilirubinemia with hepatic metastases is a common complication and a poor prognostic factor for colorectal cancer(CRC).Effective drainage is often im-possible before initiating systemic chemotherapy,owing to the liver’s diffuse metastatic involvement.Moreover,an appropriate chemotherapeutic approach for the treatment of hyperbilirubinemia is currently unavailable.CASE SUMMARY The patient,a man in his 50s,presented with progressive fatigue and severe jaundice.Computed tomography revealed multiple hepatic masses with thick-ened walls in the sigmoid colon,which was pathologically confirmed as a well-differentiated adenocarcinoma.No RAS or BRAF mutations were detected.The Eastern Cooperative Oncology Group(ECOG)performance status(PS)score was 2.Biliary drainage was impossible due to the absence of a dilated bile duct,and panitumumab monotherapy was promptly initiated.Subsequently,the bilirubin level decreased and then normalized,and the patient’s PS improved to zero ECOG score after four cycles of therapy without significant adverse events.CONCLUSION Anti-EGFR antibody monotherapy is a safe and effective treatment for RAS wild-type CRC and hepatic metastases with severe hyperbilirubinemia.

关 键 词：Colorectal neoplasms PANITUMUMAB Chemotherapy HYPERBILIRUBINEMIA JAUNDICE Case report 

分 类 号：R735.3[医药卫生—肿瘤]